REGENERON

April 9, 2021

Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission

Regeneron is pleased to confirm that Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") have asked the U.S. International Trade Commission (ITC) to terminate the case regarding the Novartis patent concerning pre-filled syringes (PFS) containing anti-vascular endothelial growth factor (anti-VEGF) medicines (U.S. Patent No. 9,220,631). Regeneron continues to believe that the '631 patent is invalid and unenforceable, and Novartis was unlawfully asserting this patent against Regeneron at the ITC. Regeneron's position is affirmed by the ITC's Office of Unfair Import Investigations ("OUII") — an independent government party to the case representing the public interest — which asserted that the '631 Patent is invalid on several grounds. Following the 200-page submission by the OUII Staff setting forth these positions in support of Regeneron, Novartis took the highly unusual action, two weeks prior to trial, of fully withdrawing its ITC complaint and terminating the ITC proceeding it had commenced.

In June 2020, Novartis also filed a parallel lawsuit in the U.S. District Court for the Northern District of New York ("NDNY") alleging infringement of the '631 patent. The NDNY suit was stayed pending the ITC proceedings but on April 8, 2021, Novartis asked that the stay be lifted.

Regeneron's antitrust lawsuit in the U.S. District Court for the Southern District of New York against Novartis and Vetter Pharma International GmbH ("Vetter") is ongoing; a copy of the public version of Regeneron's antitrust complaint is available here. We look forward to presenting our case, which we are confident will demonstrate how Novartis and Vetter are attempting to monopolize and harm competition in the U.S. anti-VEGF PFS market and Novartis is knowingly enforcing a patent that was fraudulently obtained.

Forward-Looking Statements and Use of Digital Media

This statement includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, risks associated with intellectual property of other parties and pending or future litigation relating thereto, including the proceedings discussed in this statement, the ultimate outcome of any such proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2020. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial

projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).